Holen Sie sich die Stockscreener-App
1.67
7.74%
0.12
Handel nachbörslich:
1.71
0.04
+2.40%
Schlusskurs vom Vortag:
$1.55
Offen:
$1.55
24-Stunden-Volumen:
486.55K
Relative Volume:
1.15
Marktkapitalisierung:
$101.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.86M
KGV:
-1.4911
EPS:
-1.12
Netto-Cashflow:
$-55.66M
1W Leistung:
+27.48%
1M Leistung:
+39.17%
6M Leistung:
-4.57%
1J Leistung:
-48.30%
1-Tages-Spanne:
$1.55
$1.71
1-Wochen-Bereich:
$1.33
$1.71
52-Wochen-Spanne:
$0.8551
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
925-368-8508
Adresse
427 PARK ST., CHARLOTTESVILLE
Vergleichen Sie ABOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.67 | 79.35M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
What drives Acumen Pharmaceuticals Inc. stock priceSuperior capital gains - jammulinksnews.com
Is ARTW a good long term investmentFree Investment Community - jammulinksnews.com
What analysts say about Nukkleus Inc. stockSuperior returns - jammulinksnews.com
What makes Acumen Pharmaceuticals Inc. stock price move sharplyFree Market Sentiment Analysis - Newser
Acumen Pharmaceuticals Inc. Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com
What analysts say about Acumen Pharmaceuticals Inc. stockHigh-yield trading alerts - Autocar Professional
Is Acumen Pharmaceuticals Inc. a good long term investmentRecord-breaking gains - Autocar Professional
West Pharmaceutical's Strategic Shift: How Robert McMahon's Financial Acumen Positions the Company for GLP-1 Dominance - AInvest
Central Nervous System (CNS) Biomarkers Market is expected - openPR.com
Is BKTI a good long term investmentRecord-breaking capital gains - jammulinksnews.com
Published on: 2025-07-20 14:18:28 - PrintWeekIndia
What analysts say about Rush Enterprises Inc. stockRapid wealth multiplication - jammulinksnews.com
What analysts say about BOLD stockMarket-crushing profits - jammulinksnews.com
Blue Chip Stocks Investor Friendly Stock ChoicesFree Capital Allocation Plans - Jammu Links News
Acumen and JCR enter collaboration to develop BBB-penetrating Alzheimer’s treatment - BioWorld MedTech
JCR Pharma links up with Acumen on Alzheimer’s research - The Pharma Letter
Acumen and JCR partner on brain delivery therapy for Alzheimer’s - Yahoo Finance
ai for factory safety and hazard detectionSafety First Trading Signals - Newser
Why Acumen Pharmaceuticals Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - Newser
How CURRENC Group Inc. stock performs during market volatilitySafe and Scalable Investment Tips - Newser
Acumen Pharmaceuticals Inc (ABOS) Stock: A Comprehensive 52-Week Review - investchronicle.com
How Acumen Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser
Why LINKBANCORP Inc. stock attracts strong analyst attentionPotential Rocket List - Newser
Why Veeco Instruments Inc. stock attracts strong analyst attentionFree Top Growth Stock Recommendations - Newser
How SELX stock performs during market volatilityVerified Return Tips - Newser
Acumen, JCR partner on brain barrier technology for Alzheimer’s treatment By Investing.com - Investing.com South Africa
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Acumen Pharmaceuticals, JCR to Develop Alzheimer's Disease Therapy - MarketScreener
Acumen, JCR partner on brain barrier technology for Alzheimer’s treatment - Investing.com Australia
ABOS SEC FilingsAcumen Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease - The Manila Times
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform - MarketScreener
Revolutionary Alzheimer's Treatment: Acumen and JCR Join Forces on Brain-Penetrating Drug Technology - Stock Titan
Why AFMD stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025 - The Manila Times
Acumen Pharmaceuticals to Present Findings on Sabirnetug at Alzheimer's Association International Conference 2025 - Nasdaq
New Alzheimer's Drug Trial Shows Major Cost Savings: Acumen Reveals Breakthrough Screening Method - Stock Titan
Cognition Therapeutics (CGTX) Soars 12% After-Hours on Alzheimer's Trial Data - AInvest
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):